Intas Pharmaceuticals to acquire Prothya Biosolutions.

Intas Pharmaceuticals, a vertically integrated pharmaceutical company, agreed to acquire Prothya Biosolutions, a plasma-derived medicinal products company. Financial terms were not disclosed. "We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies," Binish Chudgar, Intas Chairman.